The Role of Programmed Cell Death-1 (PD-1) and Its Ligands in Pediatric Cancer

被引:32
作者
van Dam, Laura S. [1 ]
de Zwart, Verena M. [1 ]
Meyer-Wentrup, Friederike A. G. [1 ]
机构
[1] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Hematol & Oncol, NL-3584 EA Utrecht, Netherlands
关键词
cancer immunotherapy; immune checkpoint blockade; PD-1/PD-L1; pediatric cancer; TUMOR-CELLS; POTENTIAL MECHANISM; B7-H1; EXPRESSION; B7; FAMILY; T-CELLS; RECEPTOR; BLOCKADE; SAFETY; ANTI-PD-1; ANTIBODY;
D O I
10.1002/pbc.25284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2 maintain self-tolerance and modulate physiological immune responses. Recently, targeting the PD-1/PD-L1 pathway with blocking antibodies has emerged as a potentially promising approach to treat advanced cancers in adult patients. Since tumor PD-L1 expression is currently considered the most important predictive biomarker for successful checkpoint blockade, we summarize expression data for the most common tumors of childhood. Additionally, we give an introduction into PD-1 function in the immune system to then focus on PD-1 mediated tumor immune escape. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:190 / 197
页数:8
相关论文
共 50 条
  • [41] Programmed cell death-1 in patients with primary liver cancer and its effect on prognosis
    Yang, Min
    Dou, WenWen
    Sun, GuangHong
    Zhang, YanLan
    Su, Yan
    Xie, RuiZhu
    JOURNAL OF BUON, 2019, 24 (03): : 1167 - 1174
  • [42] Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)
    Fuller, Michael J.
    Callendret, Benoit
    Zhu, Baogong
    Freeman, Gordon J.
    Hasselschwert, Dana L.
    Satterfield, William
    Sharpe, Arlene H.
    Dustin, Lynn B.
    Rice, Charles M.
    Grakoui, Arash
    Ahmed, Rafi
    Walker, Christopher M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (37) : 15001 - 15006
  • [43] Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4+ T Cell Immunity
    Karunarathne, Deshapriya S.
    Horne-Debets, Joshua M.
    Huang, Johnny X.
    Faleiro, Rebecca
    Leow, Chiuan Yee
    Amante, Fiona
    Watkins, Thomas S.
    Miles, John J.
    Dwyer, Patrick J.
    Stacey, Katryn J.
    Yarski, Michael
    Poh, Chek Meng
    Lee, Jason S.
    Cooper, Matthew A.
    Renia, Laurent
    Richard, Derek
    McCarthy, James S.
    Sharpe, Arlene H.
    Wykes, Michelle N.
    IMMUNITY, 2016, 45 (02) : 333 - 345
  • [44] Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
    Abaza, Abdelrahman
    Idris, Faten Sid
    Shaikh, Humna Anis
    Vahora, Ilma
    Moparthi, Kiran Prasad
    Al Rushaidi, Majdah T.
    Muddam, Meghana Reddy
    Obajeun, Omobolanle A.
    Jaramillo, Arturo P.
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [45] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
    Kim, Ji-Hyun
    Kim, Shinn-Young
    Shin, Eun-Young
    Jung, Ji-Han
    Choi, Hyun-Joo
    Jun, Kyong-Hwa
    ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
  • [46] Programmed cell death-1 inhibition in lymphoma
    Hawkes, Eliza A.
    Grigg, Andrew
    Chong, Geoff
    LANCET ONCOLOGY, 2015, 16 (05) : E234 - E245
  • [47] Expression of Programmed Death Receptor 1 (PD-1) Gene and Its Ligand (PD-L1) in Patients with Laryngeal Cancer
    Kowalski, Andrzej
    Malinowska, Katarzyna
    Olszewski, Jurek
    Zielinska-Blizniewska, Hanna
    BIOMOLECULES, 2021, 11 (07)
  • [48] Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction
    Wang, Yu
    Huang, Kun
    Gao, Yali
    Yuan, Dandan
    Ling, Lin
    Liu, Jieqing
    Wu, Sihai
    Chen, Roufen
    Li, He
    Xiong, Yizu
    Liu, Han
    Ma, Junjie
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 229
  • [49] Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort
    Yang, Jing
    Meng, Ling
    Yang, Yongxin
    Gao, Hongwei
    Jiang, Honggang
    NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2024, 43 (03) : 230 - 248
  • [50] Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
    Kataoka, Hiroshi
    Shimada, Daisuke
    Nanaura, Hitoki
    Sugie, Kazuma
    OXFORD MEDICAL CASE REPORTS, 2021, (09): : 330 - 332